Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Interferon-beta represses cancer stem cell properties in triple-negative breast cancer.

Doherty MR, Cheon H, Junk DJ, Vinayak S, Varadan V, Telli ML, Ford JM, Stark GR, Jackson MW.

Proc Natl Acad Sci U S A. 2017 Dec 26;114(52):13792-13797. doi: 10.1073/pnas.1713728114. Epub 2017 Dec 11.

2.

Oncostatin M promotes cancer cell plasticity through cooperative STAT3-SMAD3 signaling.

Junk DJ, Bryson BL, Smigiel JM, Parameswaran N, Bartel CA, Jackson MW.

Oncogene. 2017 Jul 13;36(28):4001-4013. doi: 10.1038/onc.2017.33. Epub 2017 Mar 13.

3.

An efficient system to fund science: from proposal review to peer-to-peer distributions.

Bollen J, Crandall D, Junk D, Ding Y, Börner K.

Scientometrics. 2017 Jan;110(1):521-528. doi: 10.1007/s11192-016-2110-3. Epub 2016 Sep 3.

4.

STAT3-mediated SMAD3 activation underlies Oncostatin M-induced Senescence.

Bryson BL, Junk DJ, Cipriano R, Jackson MW.

Cell Cycle. 2017 Feb 16;16(4):319-334. doi: 10.1080/15384101.2016.1259037. Epub 2016 Nov 28.

5.

Cancer Stem Cell Plasticity Drives Therapeutic Resistance.

Doherty MR, Smigiel JM, Junk DJ, Jackson MW.

Cancers (Basel). 2016 Jan 5;8(1). pii: E8. doi: 10.3390/cancers8010008. Review.

6.

Cancer stem cells: targeting the roots of cancer, seeds of metastasis, and sources of therapy resistance.

Adorno-Cruz V, Kibria G, Liu X, Doherty M, Junk DJ, Guan D, Hubert C, Venere M, Mulkearns-Hubert E, Sinyuk M, Alvarado A, Caplan AI, Rich J, Gerson SL, Lathia J, Liu H.

Cancer Res. 2015 Mar 15;75(6):924-9. doi: 10.1158/0008-5472.CAN-14-3225. Epub 2015 Jan 20. Review.

7.

Response: "Why we still need grant peer review".

Bollen J, Crandall D, Junk D, Ding Y, Börner K.

EMBO Rep. 2014 May;15(5):467. doi: 10.1002/embr.201438792. No abstract available.

8.

HiJAK'd Signaling; the STAT3 Paradox in Senescence and Cancer Progression.

Junk DJ, Bryson BL, Jackson MW.

Cancers (Basel). 2014 Mar 26;6(2):741-55. doi: 10.3390/cancers6020741.

9.

From funding agencies to scientific agency: Collective allocation of science funding as an alternative to peer review.

Bollen J, Crandall D, Junk D, Ding Y, Börner K.

EMBO Rep. 2014 Feb;15(2):131-3. doi: 10.1002/embr.201338068. Epub 2014 Jan 7. No abstract available.

10.

IFNβ-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage.

Cheon H, Holvey-Bates EG, Schoggins JW, Forster S, Hertzog P, Imanaka N, Rice CM, Jackson MW, Junk DJ, Stark GR.

EMBO J. 2013 Oct 16;32(20):2751-63. doi: 10.1038/emboj.2013.203. Epub 2013 Sep 24.

11.
12.

Constitutive CCND1/CDK2 activity substitutes for p53 loss, or MYC or oncogenic RAS expression in the transformation of human mammary epithelial cells.

Junk DJ, Cipriano R, Stampfer M, Jackson MW.

PLoS One. 2013;8(2):e53776. doi: 10.1371/journal.pone.0053776. Epub 2013 Feb 4.

13.

dNTP Supply Gene Expression Patterns after P53 Loss.

Radivoyevitch T, Saunthararajah Y, Pink J, Ferris G, Lent I, Jackson M, Junk D, Kunos CA.

Cancers (Basel). 2012 Nov 20;4(4):1212-24. doi: 10.3390/cancers4041212.

14.

[Flow diverter: a new therapy option for intracranial aneurysms].

Simgen A, Junk D, Reith W.

Radiologe. 2012 Dec;52(12):1118-24. doi: 10.1007/s00117-012-2373-5. German.

PMID:
23178787
15.

[Treatment of high grade intracranial stenoses].

Dietrich P, Roth C, Simgen A, Junk D, Reith W.

Radiologe. 2012 Dec;52(12):1112-7. doi: 10.1007/s00117-012-2372-6. German.

PMID:
23178786
16.

A comparison of 2 stroke devices: the new Aperio clot-removal device and the solitaire AB/FR.

Roth C, Junk D, Papanagiotou P, Keuler A, Körner H, Schumacher M, Reith W.

AJNR Am J Neuroradiol. 2012 Aug;33(7):1317-20. doi: 10.3174/ajnr.A2962. Epub 2012 Feb 2.

17.

p53 induces distinct epigenetic states at its direct target promoters.

Vrba L, Junk DJ, Novak P, Futscher BW.

BMC Genomics. 2008 Oct 15;9:486. doi: 10.1186/1471-2164-9-486.

18.
19.

Sex-specific expression of alternative transcripts in Drosophila.

McIntyre LM, Bono LM, Genissel A, Westerman R, Junk D, Telonis-Scott M, Harshman L, Wayne ML, Kopp A, Nuzhdin SV.

Genome Biol. 2006;7(8):R79. Epub 2006 Aug 25.

20.

Changes in polyphenols of the seed coat during the after-darkening process in pinto beans (Phaseolus vulgaris L.).

Beninger CW, Gu L, Prior RL, Junk DC, Vandenberg A, Bett KE.

J Agric Food Chem. 2005 Oct 5;53(20):7777-82.

PMID:
16190630
21.

Epigenetic silencing of DSC3 is a common event in human breast cancer.

Oshiro MM, Kim CJ, Wozniak RJ, Junk DJ, Muñoz-Rodríguez JL, Burr JA, Fitzgerald M, Pawar SC, Cress AE, Domann FE, Futscher BW.

Breast Cancer Res. 2005;7(5):R669-80. Epub 2005 Jun 16.

22.

The acetyltransferase p300/CBP-associated factor is a p53 target gene in breast tumor cells.

Watts GS, Oshiro MM, Junk DJ, Wozniak RJ, Watterson S, Domann FE, Futscher BW.

Neoplasia. 2004 May-Jun;6(3):187-94.

23.

Mutant p53 and aberrant cytosine methylation cooperate to silence gene expression.

Oshiro MM, Watts GS, Wozniak RJ, Junk DJ, Munoz-Rodriguez JL, Domann FE, Futscher BW.

Oncogene. 2003 Jun 5;22(23):3624-34.

PMID:
12789271
24.

Supplemental Content

Support Center